(-)-7-辛基吲哚内酰胺V | 109346-66-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (-)-7-辛基吲哚内酰胺V
• 英文名称: 7-(n-octyl)-ILV
• 英文别名: (-)-7-octylindolactam V；octylindolactam V；7-octylindolactam-V；7-Octylindolactam V；(10S,13S)-13-(hydroxymethyl)-9-methyl-5-octyl-10-propan-2-yl-3,9,12-triazatricyclo[6.6.1.04,15]pentadeca-1,4,6,8(15)-tetraen-11-one
• CAS: 109346-66-9
• 化学式: C₂₅H₃₉N₃O₂
• 分子量: 413.604
• InChiKey: SUQYTYOVPXAUGB-RDPSFJRHSA-N

物化性质

• 稳定性/保质期：

  常温常压下稳定，避免与强酸和强碱接触。

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  68.4
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 安全说明：
  S22,S24/25

反应信息

• 作为产物：
  描述：

  1-辛基氯化镁, 1M IN METHF 在 palladium on activated charcoal 2,6-二甲基吡啶 、 锂硼氢 、 dimethyl sulfide borane 、 氢气 、 sodium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 生成 (-)-7-辛基吲哚内酰胺V
  参考文献：
  名称：

  Protein kinase C modulators. Indolactams. 2.1 Alkylation of 4-nitroindole by Grignard reagents. Synthesis of (-)-7-octylindolactam V

  摘要：

  A method for the C-alkylation of 4-nitroindole at the 5 and 7 positions by alkyl Grignard reagents has been developed. The 4-nitro-7-octylindole thus prepared has been used as a starting material for the synthesis of the lyngbyatoxin analog, (-)-7-octylindolactam V.

  DOI：

  10.1016/s0040-4039(00)78434-6

文献信息

• PKC activators and combinations thereof
  申请人：Cognitive Research Enterprises, Inc.

  公开号：US10821079B2

  公开（公告）日：2020-11-03

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。该公开进一步涉及这些组合物的组成、试剂盒、用途和方法。
• Synthesis and Biological Activities of (-)-6-<i>n</i>-Octyl-indolactam-V, a New Potent Analogue of the Tumor Promoter (-)-Indolactam-V
  作者：Yu NAKAGAWA、Kazuhiro IRIE、Yoshimasa NAKAMURA、Hajime OHIGASHI、Hideo HAYASHI

  DOI：10.1271/bbb.62.1568

  日期：1998.1

  (-)-Indolactam-V (1) without a hydrophobic chain at positions 6 and 7 of the indole ring is a weak tumor promoter compared with teleocidin Bs. To investigate the effects of the hydrophobic substituent at position 6 of teleocidin Bs, we synthesized (-)-6-n-octyl-indolactam-V (2) by a palladium-catalyzed coupling reaction from (-)-6-bromo-indolactam-V (7) which had been obtained by microbial conversion with Streptoverticillium blastmyceticum NA34-17 as the key step. (-)-7-n-Octyl-indolactam-V (3) with potent biological activities comparable to those of teleocidin Bs was similarly synthesized from (-)-7-bromo-indolactam-V as a positive control. Compound 2 showed similar biological activities to those of 3, indicating that the effect of the hydrophobic substituent at position 6 of 1 was identical to that at position 7.

  与 teleocidin Bs 相比，吲哚环 6 和 7 位没有疏水链的 (-)-Indolactam-V (1) 是一种弱肿瘤促进剂。为了研究 teleocidin Bs 第 6 位疏水取代基的影响，我们以(-)-6-溴-吲哚内酰胺-V (7)为原料，通过钯催化偶联反应合成了(-)-6-正辛基-吲哚内酰胺-V (2)。以(-)-7-溴-吲哚内酰胺-V 为阳性对照，同样合成了(-)-7-正辛基-吲哚内酰胺-V (3)，其生物活性与 teleocidin Bs 相当。化合物 2 显示出与 3 类似的生物活性，表明 1 的第 6 位疏水取代基与第 7 位疏水取代基的作用相同。
• PKC ACTIVATORS AND COMBINATIONS THEREOF
  申请人：BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE

  公开号：US20140315990A1

  公开（公告）日：2014-10-23

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。本公开进一步涉及其组成物、套件、用途和方法。
• Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
  申请人：Blanchette Rockefeller Neurosciences Institute

  公开号：EP2737904A2

  公开（公告）日：2014-06-04

  The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke.

  本发明提供了使用蛋白激酶激活剂或神经生长因子（NGF）、脑源性神经营养因子（BDNF）或其他神经营养因子的促进剂治疗中风的方法。具体而言，本发明提供了治疗中风的方法，包括以下步骤：确定中风患者，并向所述患者施用一定量的药物组合物，该药物组合物包含蛋白激酶 C (PKC) 激活剂或 4-甲基邻苯二酚乙酸 (MCBA) 和药学上可接受的载体，可有效治疗中风的至少一种症状。
• Treatment of depressive disorders
  申请人：Blanchette Rockefeller Neuroscience Institute

  公开号：US10010584B2

  公开（公告）日：2018-07-03

  The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds to treat depressive disorders.

  本发明提供了使用碳酸酐酶激活剂、蛋白激酶 C 激活剂和 FGF-18 治疗抑郁障碍的方法。本发明还涉及用于筛选和鉴定治疗抑郁障碍的化合物的改良动物模型和方法。